CureGene Achieves First Participant Dosed in U.S. Pivotal Trial for Evategrel (CG-0255), a Best-in-Class Antiplatelet Drug, Accelerating Global Commercialization
- CureGene Pharmaceutical dosed the first participant in the U.S. pivotal clinical trial of Evategrel , a new best-in-class antiplatelet drug.
- This trial is a key step toward submitting a New Drug Application in the U.S. and aims to help millions of patients with cardiovascular and cerebrovascular diseases globally.
- Evategrel is the first P2Y12 receptor inhibitor available in both intravenous and oral forms and uses a prodrug design that bypasses the CYP450 enzyme pathway.
- The ongoing trial compares the efficacy and safety of Evategrel against clopidogrel in patients with acute coronary syndrome, myocardial infarction, ischemic stroke, and peripheral arterial disease.
25 Articles
25 Articles
The Times of Northwest Indiana
CureGene Achieves First Participant Dosed in U.S. Pivotal Trial for Evategrel (CG-0255), a Best-in-Class Antiplatelet Drug, Accelerating Global Commercialization
SHANGHAI, June 20, 2026 /PRNewswire/ -- CureGene Pharmaceutical today announced that the first participant has been successfully dosed in the U.S. pivotal clinical trial of Evategrel (CG-0255), its proprietary new-generation best-in-class antiplatelet agent. This milestone marks a critical step toward…
CureGene Achieves First Participant Dosed in U.S. Pivotal Trial for Evategrel (CG-0255), a Best-in-Class Antiplatelet Drug, Accelerating Global Commercialization - PressReach
SHANGHAI, June 20, 2026 /PRNewswire/ — CureGene Pharmaceutical today announced that the first participant has been successfully dosed in the U.S. pivotal clinical trial of Evategrel (CG-0255), its proprietary new-generation best-in-class antiplatelet agent. This milestone marks a critical step toward the New Drug Application (NDA) submission in the United States and brings new hope to millions of patients with cardiovascular and cerebrovascular …
Coverage Details
Bias Distribution
- 59% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
